01390nas a2200445   4500000000100000000000100001008004100002260001500043653001600058653001800074653002000092653002400112653002300136653002800159653001200187100002400199700001600223700001900239700001600258700001500274700001900289700002100308700002100329700001900350700001600369700001700385700002000402700001900422700002100441700001800462700001600480700002500496700002300521700001500544700001900559245011100578856005500689520018600744022001400930       2025                            d  c2025-03-0610abiomedicine10aBiotechnology10aCancer Research10aMedicinal Chemistry10aMolecular medicine10aPharmacology/Toxicology10ageneral1 aAndrew S. Robertson1 aNahid Latif1 aImein Bousnina1 aDonna Boyce1 aKevin Carl1 aSean P. Curtis1 aJennifer Dudinak1 aCarlos O. Garner1 aMichael Garvin1 aSabine Luik1 aEddie Reilly1 aMichelle Rohrer1 aKatrin Rupalla1 aJacintha Shenton1 aJerry Stewart1 aMark Taisey1 aRaymond C. Votzmeyer1 aMatthew P. Wagoner1 aMax Wegner1 aKathy Williams00aAccelerating adoption of new approach methodologies in regulatory decision making: an industry perspective  uhttps://www.nature.com/articles/d41573-025-00038-63 aClear and harmonized regulatory guidelines are needed to realize the potential of new approach methodologies for improving the predictivity of nonclinical drug candidate assessment.  a1474-1784